TMRW Life Sciences ("TMRW") is the creator of ivfOS™, an integrated platform for automated, software-guided embryology and cryo-management.
TMRW is revolutionizing in vitro fertilization with the first automated and robotic cryo-management platform devoted to IVF.
TMRW Life Sciences was founded in 2018 by Joshua Abram, Alan Murray and Jeff Port. The company is headquartered in New York City, New York.
The TMRW ivfOS revolutionizes the management, identification, and storage of fertility cells — replacing the error-prone manual and analog methods that have remained largely unchanged since IVF was first used in animal husbandry more than fifty years ago.
TMRW’s technology significantly reduces the risk of loss or misidentification of the precious cells used in IVF. TMRW’s technology will play a central role in the conception of tens of millions of people in the coming years.
TMRW's RFID-enabled, 100% digital chain of custody SaaS platform radically improves on the error-prone manual and analog methods that have gone unchanged throughout the history of IVF, significantly reducing the chances of implantation mix-ups or loss of eggs and embryos.
TMRW Life Sciences is backed by Special Situations Life Sciences Innovation Fund and 5AM Ventures. The company raised $25M in a Series B financing on Dec 17, 2019. This new round brings TMRW's total funding to $37M to date.